Antiviral Therapy for Chronic HCV Infection: Virological Response and Long-Term Outcome

摘要: markdownabstract__Abstract__ Hepatitis C is a major global health problem which responsible for over 350,000 deaths each year.1 In total, there are thought to be around 150 million hepatitis virus (HCV) carriers, comprise about 3% of the world population. The prevalence of HCV infection, however, shows substantial geographical variation. Europe the prevalence infection varies from 0.1 6.0%, with highest occurrence in Southern and Eastern Europe.2 Netherlands represents country in HCV infection not frequently observed. A recently performed Dutch epidemiological study indicated that seroprevalence anti-HCV antibodies was 0.3%, around the lowest world.3 Nevertheless, this would mean almost 40,000 inhabitants of have been contact HCV, leading approximately 30,000 patients chronic infection. First-generation migrants from HCV-endemic countries injecting drug users (IDU) form most important risk groups Netherlands.